Insmed

Bewertungs-Analyse

★ Smart Money Investoren

Diese Aktie wird von einem oder mehreren unserer 15 getrackten Smart Money Manager gehalten. Klicke auf einen Namen um das vollständige Portfolio zu sehen.

Über das Unternehmen

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation p

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich Insmed kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.